Sep 05, 2023 7:00am EDT Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 21, 2023 7:00am EDT Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Aug 14, 2023 7:00am EDT Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Jul 13, 2023 7:00am EDT Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jul 06, 2023 7:00am EDT Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Jun 12, 2023 7:00am EDT Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
